湖南省某专科医院非结核分枝杆菌临床分离株菌种鉴定及药敏结果

doi:10.12138/j.issn.1671-9638.20216570

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (797 KB) HTML ()
输出: BibTeX | EndNote (RIS)

摘要目的探讨非结核分枝杆菌肺病（NTMPD）菌种分布及耐药性，为其临床诊治提供依据。方法收集2017—2019年湖南省某胸科医院BACTEC MGIT 960系统培养阳性的临床分离菌株，经MPB64检测以及PNB、TCH培养基生长试验分离出非结核分枝杆菌（NTM），应用16Sr RNA、Hsp65、ITS基因测序法将NTM鉴定至种，采用最低抑菌浓度（MIC）法检测其中脓肿分枝杆菌对10种抗菌药物的耐药性。结果 10 443份MGIT 960报告阳性的菌株中，共检出NTM 1 227株，检出率为11.7%。经菌种鉴定，居前4位者依次为胞内分枝杆菌（27.8%）、脓肿分枝杆菌（25.3%）、戈登分枝杆菌（16.5%）、鸟分枝杆菌（16.1%）。脓肿分枝杆菌对阿米卡星、克拉霉素和利奈唑胺的敏感性较高，敏感率分别是94.6%、87.5%、82.1%；对其他药物的敏感率均低于50%。结论湖南省NTM流行的菌种以脓肿分枝杆菌和胞内分枝杆菌为主，阿米卡星和克拉霉素可作为该省临床治疗脓肿分枝杆菌感染患者的优选抗菌药物。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	陈振华
	胡培磊
	易松林
	张小萍
	段洁
	刘昭国
	谭云洪

关键词 ：非结核分枝杆菌, 脓肿分枝杆菌, 菌种, 抗菌药物, 药敏试验, 非结核分枝杆菌肺病

Abstract：Objective To investigate species distribution and antimicrobial resistance of non-tuberculous mycobacterial pulmonary disease (NTMPD), and provide basis for clinical diagnosis and treatment. Methods Positive clinical isolates cultured with BACTEC MGIT 960 system in a chest hospital in Hunan Province from 2017 to 2019 were collected, non-tuberculous mycobacteria (NTM) was isolated by MPB64 detection and PNB/TCH medium growth testing, NTM species were identified by 16Sr RNA, Hsp65 and ITS gene sequencing, resistance of Mycobacterium abscessus to 10 kinds of antimicrobial agents was detected with minimal inhibitory concentration (MIC) method. Results Among 10 443 positive strains reported by MGIT 960, 1 227 NTM strains were isolated, isolation rate was 11.7%. The top 4 strains were Mycobacterium intracellulare (27.8%), Mycobacterium abscessus (25.3%), Mycobacterium gordonae (16.5%) and Mycobacterium avium (16.1%). Susceptibility rates of Mycobacterium abscessus to amikacin, clarithromycin and linezolid were high, which were 94.6%, 87.5% and 82.1% respectively, while susceptibility rates to other antimicrobial agents were all lower than 50%. Conclusion Mycobacterium abscessus and Mycobacterium intracellular are the most prevalent strains of NTM in Hunan Province, amikacin and clarithromycin can be used as the preferred antimicriobial agents for clinical treatment of patients with Mycobacte-rium abscessus infection in Hunan Province.

Key words： non-tuberculous mycobacteria Mycobacterium abscessus species antimicrobial agent antimicrobial susceptibility testing non-tuberculous mycobacterial pulmonary disease

收稿日期: 2020-03-06

PACS:

R181.3+2

通讯作者: 谭云洪 E-mail: tanyunhong@163.com

作者简介: 陈振华(1982-),男(汉族),湖南省衡阳市人,副主任技师,主要从事结核病实验室检测。

引用本文:

陈振华, 胡培磊, 易松林, 张小萍, 段洁, 刘昭国, 谭云洪. 湖南省某专科医院非结核分枝杆菌临床分离株菌种鉴定及药敏结果[J]. 中国感染控制杂志, 2021, 20(4): 361-365. CHEN Zhen-hua, HU Pei-lei, YI Song-lin, ZHANG Xiao-ping, DUAN Jie, LIU Zhao-guo, TAN Yun-hong. Species identification and antimicrobial susceptibility testing result of clinically isolated non-tuberculous mycobacteria in a specialized hospital in Hunan Province. Chinese Journal of Infection Control, 2021, 20(4): 361-365.

链接本文:

http://www.zggrkz.com/CN/10.12138/j.issn.1671-9638.20216570 或 http://www.zggrkz.com/CN/Y2021/V20/I4/361

[1]	Lopeman RC, Harrison J, Desai M, et al. Mycobacterium abscessus:environmental bacterium turned clinical nightmare[J]. Microorganisms, 2019, 7(3):90.
[2]	李仲兴. 非结核分枝杆菌与临床感染[M]. 北京:科学出版社, 2015.
[3]	李欣影, 严彩丽, 钟慧婷. 手术切口非结核分枝杆菌感染1例[J]. 中国感染控制杂志, 2014, 13(9):568-570.
[4]	Zhang ZX, Cherng BPZ, Sng LH, et al. Clinical and microbiological characteristics of non-tuberculous mycobacteria diseases in Singapore with a focus on pulmonary disease, 2012-2016[J]. BMC Infect Dis, 2019, 19(1):436.
[5]	Cowman S, van Ingen J, Griffith DE, et al. Non-tuberculous mycobacterial pulmonary disease[J]. Eur Respir J, 2019, 54(1):1900250.
[6]	Sharma SK, Sharma R, Singh BK, et al. A prospective study of non-tuberculous mycobacterial disease among tuberculosis suspects at a tertiary care centre in North India[J]. Indian J Med Res, 2019, 150(5):458-467.
[7]	楼海, 孙勤, 顾瑾, 等. 常见非结核分枝杆菌肺病的临床特征及药物敏感试验结果分析[J]. 中华结核和呼吸杂志, 2019, 42(12):901-906.
[8]	赵雁林, 逄宇. 结核病实验室检验规程[M]. 北京:人民卫生出版社, 2015:15-53.
[9]	Woods GL, Brown-Elliott BA, Conville PS, et al. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard-second edition:M24-A2[S]. Wayne, PA:Clinical and Laboratory Standards Institute, 2011.
[10]	全国第五次结核病流行病学抽样调查技术指导组, 全国第五次结核病流行病学抽样调查办公室. 2010年全国第五次结核病流行病学抽样调查报告[J]. 中国防痨杂志, 2012, 34(8):485-508.
[11]	Cowman S, Burns K, Benson S, et al. The antimicrobial susceptibility of non-tuberculous mycobacteria[J]. J Infect, 2016, 72(3):324-331.
[12]	Chin KL, Sarmiento ME, Alvarez-Cabrera N, et al. Pulmonary non-tuberculous mycobacterial infections:current state and future management[J]. Eur J Clin Microbiol Infect Dis, 2020, 39(5):799-826.
[13]	Musaddaq B, Cleverley JR. Diagnosis of non-tuberculous mycobacterial pulmonary disease (NTM-PD):modern challenges[J]. Br J Radiol, 2020, 93(1106):20190768.
[14]	中华医学会结核病学分会, 非结核分枝杆菌病实验室诊断专家共识编写组. 非结核分枝杆菌病实验室诊断专家共识[J]. 中华结核和呼吸杂志, 2016, 39(6):438-443.
[15]	Schiff HF, Jones S, Achaiah A, et al. Clinical relevance of non-tuberculous mycobacteria isolated from respiratory specimens:seven year experience in a UK hospital[J]. Sci Rep, 2019, 9(1):1730.
[16]	刘东鑫, 郑惠文, 贺文从, 等. 广州市非结核分枝杆菌临床分离株菌种鉴定及药物敏感性试验结果分析[J]. 中国防痨杂志, 2019, 41(5):534-540.
[17]	Wetzstein N, Hügel C, Wichelhaus TA, et al. Species distribution and clinical features of infection and colonisation with non-tuberculous mycobacteria in a tertiary care centre, central Germany, 2006-2016[J]. Infection, 2019, 47(5):817-825.
[18]	Gomathy NS, Padmapriyadarsini C, Silambuchelvi K, et al. Profile of patients with pulmonary non-tuberculous mycobacterial disease mimicking pulmonary tuberculosis[J]. Indian J Tuberc, 2019, 66(4):461-467.
[19]	Hatakeyama S, Ohama Y, Okazaki M, et al. Antimicrobial susceptibility testing of rapidly growing mycobacteria isolated in Japan[J]. BMC Infect Dis, 2017, 17(1):197.